Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Recruiting 2Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9Genitourinary 4Gastrointestinal 3CNS 3Other 2Head & Neck 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Multiple Myeloma 292Lymphoma 45Recurrence 31Neoplasms, Plasma Cell 28Hematologic Neoplasms 25Smoldering Multiple Myeloma 20Lymphoma, Non-Hodgkin 20Neoplasms 13Leukemia, Lymphocytic, Chronic, B-Cell 11Myelodysplastic Syndromes 10Leukemia 10Immunoglobulin Light-chain Amyloidosis 10Leukemia, Myeloid, Acute 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myeloproliferative Disorders 8Hodgkin Disease 8Waldenstrom Macroglobulinemia 7Lymphoma, Mantle-Cell 6Prostatic Neoplasms 5Paraproteinemias 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Breast Neoplasms 5Lymphoproliferative Disorders 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hematologic Diseases 4Colorectal Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Anemia, Aplastic 4

Interventions

daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Disease × Plasma cell × Clear all
NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

European Myeloma Network B.V.

Phase 2 Active not recruiting
401 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡